315 completed, 47 unknown, 37 terminated, 16 recruiting. 442 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 442 | Completed 315, Unknown 47, Terminated 37, Recruiting 16, Withdrawn 11, Active not recruiting 9, Not yet recruiting 5, Enrolling by invitation 2 |
Follow Asthma: new trials by email Literature Review of Asthma trials Research Report on Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prevent Wheeze Trial Dexamethasone 0.6 mg/kilogram body weight single dose, Placebo - Lower Respiratory Tract Infection (LRTI), Recurrent Wheezing | Phase 4 | Not yet recruiting | Norwegian University of Science and Technology | 486 | 2027-02-01 | 2026-10-05 |
| Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate Fluticasone Propionate, Water Mouthwash, EVOOW Mouthwash - Asthma | Phase 4 | Not yet recruiting | University of Wisconsin, Madison | 20 | 2026-11-01 | 2026-11-05 |
| Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice ALK Alutard SQ Dog - Allergic Rhinitis, Asthma (Diagnosis) | Phase 4 | Recruiting | Karolinska Institutet | 40 | 2026-08-01 | 2026-06-29 |
| Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department Dexamethasone 16mg IM, Prednisone 60mg PO - Asthma | Phase 4 | Recruiting | Montefiore Medical Center | 182 | 2026-07-23 | 2026-07-24 |
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg]) Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation), Foster® 200/6 pMDI (BDP/FF-200/6 µg) - Asthma | Phase 4 | Recruiting | Chiesi Farmaceutici S.p.A. | 644 | 2026-06-28 | 2026-07-31 |
| Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) Tezepelumab, Placebo - Severe Asthma | Phase 4 | Recruiting | University of Alberta | 100 | 2026-05-11 | 2026-07-17 |
| Ventilation and Perfusion in Asthmatics Albuterol Sulfate, Albuterol-Budesonide - Asthma | Phase 4 | Recruiting | University of Miami | 40 | 2026-04-27 | 2026-10-23 |
| CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma Implementation bundle - Moderate to Severe Asthma | Phase 4 | Recruiting | Washington University School of Medicine | 2000 | 2026-01-06 | 2026-09-10 |
| Withdrawal of Dupilumab in Severe Asthma Stopping dupilumab - Severe Asthma | Phase 4 | Recruiting | University Hospital, Toulouse | 205 | 2025-12-15 | 2026-10-08 |
| 45th Multicenter Airway Research Collaboration Airsupra - Asthma Acute, Asthma Exacerbation | Phase 4 | Recruiting | Massachusetts General Hospital | 1860 | 2025-11-07 | 2026-04-17 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| IV DEXAMETHASONE VS. METHYLPREDNISOLONE IN CHILDREN WITH SEVERE ASTHMA EXACERBATION Intravenous Dexamethasone, Intravenous Methylprednisolone - Status Asthmaticus, Asthma (Diagnosis) | Phase 4 | Completed | Istanbul Medeniyet University | 129 | 2025-09-01 | 2026-07-28 |
| Individualizing Treatment for Asthma in Primary Care (Full Study) Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application - Asthma, Asthma Attack | Phase 4 | Recruiting | DARTNet Institute | 3200 | 2025-08-01 | 2025-10-29 |
| Therapeutic Relevance of Abnormal Airway Morphology in Asthma Inhaled corticosteroid (ICS), Oral Corticosteroid (OCS) - Asthma | Phase 4 | Recruiting | McMaster University | 242 | 2025-06-02 | 2025-09-11 |
| Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response Tiotropium (Spiriva®), Placebo - Asthma Bronchiale | Phase 4 | Not yet recruiting | University of Saskatchewan | 10 | 2025-01-01 | 2024-11-07 |
| Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients. Budesonide-Formoterol treatment - Cough-Variant Asthma | Phase 4 | Completed | AstraZeneca | 1000 | 2024-10-18 | 2025-09-18 |
| Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma Albuterol/Budesonide, Albuterol - Mild Asthma | Phase 4 | Completed | AstraZeneca | 101 | 2024-09-11 | 2026-02-27 |
| Evaluation of Time-Sensitive Nebulization Mode Converter Cross-over Nebulization Modes Comparison System - Aerosol Therapy, Asthma | Phase 4 | Completed | Beni-Suef University | 36 | 2024-09-01 | 2026-06-08 |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma dupilumab, Matching Placebo, ICS/LABA - Asthma | Phase 4 | Active not recruiting | Regeneron Pharmaceuticals | 120 | 2024-08-26 | 2026-05-22 |
Showing 20 of 442. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (25) · Rhinitis, Allergic (17) · Pulmonary Eosinophilia (15) · Respiratory Sounds (10) · Emergencies (9) · Cough-Variant Asthma (8) · Respiratory Hypersensitivity (8) · Asthma, Exercise-Induced (7) · Inflammation (6) · Status Asthmaticus (6) · Hypersensitivity (5) · Lung Diseases (5) · Motor Activity (5) · Dermatitis, Atopic (4)
Hypersensitivity, Immediate (441) · Bronchial Diseases (439) · Immune System Diseases (439) · Respiratory Tract Diseases (439) · Hypersensitivity (437) · Respiratory Hypersensitivity (434) · Lung Diseases, Obstructive (433) · Lung Diseases (430) · Pathological Conditions, Signs and Symptoms (62) · Pathologic Processes (43) · Disease Attributes (34) · Otorhinolaryngologic Diseases (26) · Chronic Disease (25) · Nose Diseases (24) · Hemic and Lymphatic Diseases (20)
Albuterol (48) · Fluticasone (47) · montelukast (46) · Budesonide (38) · Fluticasone-Salmeterol Drug Combination (34) · Omalizumab (24) · Salmeterol Xinafoate (21) · Beclomethasone (16) · Formoterol Fumarate (16) · Budesonide, Formoterol Fumarate Drug Combination (13) · Mometasone Furoate (12) · dupilumab (12) · mepolizumab (12) · Azithromycin (10) · Ipratropium (10)
GlaxoSmithKline (53) · AstraZeneca (23) · Organon and Co (19) · University of Dundee (12) · University of Saskatchewan (12) · Medical University of Lodz (9) · Centre of Chinese Medicine, Georgia (8) · Imperial College London (8) · Bispebjerg Hospital (6) · Boehringer Ingelheim (6) · Novartis (6) · Novartis Pharmaceuticals (6) · Teva Branded Pharmaceutical Products R&D, Inc. (6) · University of California, San Francisco (6) · University of Florida (5)
United States (155) · Canada (57) · United Kingdom (48) · Germany (30) · Denmark (23) · Italy (22) · China (21) · Spain (21) · France (20) · Netherlands (20) · Poland (20) · Belgium (18) · Sweden (15) · Brazil (11) · Argentina (9)
Don Cockcroft, MD (6) · Iwona Stelmach, MD, PhD, Prof (6) · Manana Tchaia, MD (6) · Merab Lomia, MD, PhD (6) · Brian Lipworth, MD (5) · Leslie Hendeles, PharmD (4) · Tamara Tchelidze, MD (4) · Brian J Lipworth, MBchB (3) · C H Razi, MD (3) · Donald W Cockcroft, MD (3)
PMID 20167147, PMID 32298853, PMID 33369570, PMID 36472162, PMID 37347518, PMID 37536444, PMID 37952772, PMID 10109801, PMID 11113831, PMID 11825832, PMID 12045120, PMID 12612294, PMID 15823451, PMID 15922813, PMID 16226443, PMID 16478839, PMID 16597501, PMID 16687712, PMID 17046300, PMID 17075269, PMID 17507702, PMID 17610727, PMID 17629923, PMID 17766511, PMID 18331513, PMID 18583517, PMID 18951618, PMID 18990678, PMID 19127072, PMID 19134016, PMID 19164187, PMID 19291931, PMID 19467341, PMID 19496252, PMID 19557208, PMID 19632710, PMID 19663124, PMID 19696440, PMID 19804441, PMID 19910613, PMID 20298399, PMID 20429821, PMID 20509942, PMID 20595145, PMID 20622031, PMID 20801010, PMID 20802165, PMID 20851928, PMID 20887423, PMID 21037369
2019 (6), 2015 (4), 2014 (3), 2017 (3), 2005 (2), 2016 (2), 2018 (2), 2023 (2), 2025 (2), K23HL171940 (1), P01HL128191 (1), P50HL056385 (1), R01HL080414 (1), R01HL114899 (1), R01HL161362 (1)